Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,553 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

Lubiprostone in Children With Functional Constipation

NCT02042183
Conditions
Constipation - Functional
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
87
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 78 more
Conditions
Head and Neck Cancer
Interventions
cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
259
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more
Conditions
Metastatic HER2-positive Breast Cancer
Interventions
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more
Conditions
Metastatic Breast Cancer
Interventions
DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
44
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more
Conditions
Articular Fractures
Interventions
Single Implant Fixation, Dual Implant Fixation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 13 more
Conditions
Sickle Cell Disease
Interventions
Oxbryta® (voxelotor) 500mg Tablets
Drug
Lead sponsor
Pfizer
Industry
Eligibility
4 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
43
States / cities
Mobile, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Conditions
Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
Conditions
Anemia, Renal Diseases
Interventions
epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
66
States / cities
Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
Conditions
Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions
Cofetuzumab Pelidotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more
Recruiting No phase listed Observational

Product Surveillance Registry

NCT01524276
Conditions
Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2040
U.S. locations
136
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 133 more
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Drug · Device
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Paragould, Arkansas • Pine Bluff, Arkansas • Alhambra, California + 31 more
Conditions
Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
6 Years to 16 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Conditions
Breast Cancer
Interventions
gemcitabine/carboplatin, Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
102
States / cities
Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more
Conditions
Anemia
Interventions
Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Azusa, California • Los Angeles, California • Whittier, California + 16 more
Conditions
Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
11,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
176
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 141 more
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Not listed No phase listed Observational Accepts healthy volunteers

Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders

NCT03812055
Conditions
Lysosomal Storage Diseases
Interventions
Not listed
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Fabry Disease
Interventions
migalastat HCl 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia
Conditions
Microsatellite Stable Metastatic Colorectal Cancer
Interventions
Evorpacept (ALX148), Cetuximab, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more
Conditions
Pancreatic Cancer Non-resectable
Interventions
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 28 more
Completed Phase 3 Interventional Results available

Performance of the Hedrocel(R) Cervical Fusion Device

NCT00758758
Conditions
Symptomatic Cervical Disc Disease
Interventions
Anterior Cervical Discectomy and Fusion
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
13
States / cities
Los Angeles, California • Clearwater, Florida • Orlando, Florida + 9 more
Conditions
Bladder Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more